Skip to main content
. 2021 Jul 22;6(14):e145875. doi: 10.1172/jci.insight.145875

Figure 5. DX1 suppresses tumor growth and prolongs survival in a 231-BR orthotopic model of breast cancer brain metastases.

Figure 5

Formation and growth of brain metastases in mice after intracardiac injection of luciferase-expressing 231-BR cells was followed by monitoring radiance efficiency in the brain. One week after injection, mice began treatment with i.v. control buffer (group 1) or DX1 (20 mg/kg, group 2). Weekly IVIS demonstrated significant suppression of tumor growth by DX1 delivered as 1 or 4 cycles. (A–D) Radiance efficiencies are plotted (A–C), and representative IVIS images from week 5 of the 4 cycle study are shown (D). *P < 0.04, **P ≤ 0.01. Student’s t test; numbers of mice evaluated at each point are indicated in the plots. (E) One cycle of DX1 was associated with a nonsignificant increase in median survival to 35 days, compared with 30 days in control mice (P = 0.42, log-rank test, n = 7). (F) Four cycles of DX1 had a greater effect, with median survival prolonged to 45 days, compared with 31 days in control mice (P < 0.02, log-rank test, n = 7).